TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity.
Michael F KaminskiLaura BendzickRachel HoppsMarissa KauffmanBehiye KodalYvette SoignierPeter HinderlieJoshua T WalkerTodd R LenvikMelissa A GellerJeffrey S MillerMartin FelicesPublished in: Journal for immunotherapy of cancer (2022)
Our findings indicate that the cam1615TEM8 TriKE is a novel anti-tumor, anti-stroma, and anti-angiogenic cancer therapy for patients with solid tumors. This multifunctional molecule works by selectively targeting and activating NK cells by costimulation with IL-15, and then targeting that activity to TEM8+ tumor cells and TEM8+ tumor stroma.